We have been issued a US patent covering the use of TA and other antifibrinolytics for anti-aging effects. Our lead product will be a topical facial TA gel or lotion to reduce fine lines and wrinkles. By reducing the production of plasmin and through other mechanisms, TA has been shown in extensive animal and (in part) human research to reduce the degradation of collagen, maintain skin flexibility and thickness, reduce inflammation, support the immune system, improve mitochondrial function, reduce melasma (dark spots) and rosacea, and avoid development of skin cancers. In addition, we believe that a daily use TA facial product will reduce the number of cold sore outbreaks based on our in vitro and animal research and limited clinical cases using TA against the Herpes virus. A facial product with FDA approval for the reduction of fine lines and wrinkles through improved skin health (as opposed simply to increased hydration or injection of foreign materials) that also serves to reduce cold sore outbreaks, melasma, and possibly skin cancers will be a blockbuster in the $150 billion global skin care market.
Ongoing product line extensions could include a body cream for the same benefits for the skin on other parts of the body. Topical products for treatment of outbreaks of Herpes (cold sores, genital, shingles, other), possibly with a higher concentration of TA, could also be included. A daily oral product will also be considered, since it has been shown in mice to improve skin and overall health, and extend the lifespan. Effects in mice are not always obtained in humans, but TA’s proven effects in humans listed above such as reducing inflammation, improving the immune system, and reducing viral outbreaks could logically provide improvement in overall health, reduced susceptibility to disease, and increased lifespan.
